Table 1.
Group | Phase 1 | Phase 2 | Phase 3 | Test |
---|---|---|---|---|
Inflate-XT | 9 B-/9 A–US/84 AX- | 30 A–US/30 D- | 4 T–US | XT |
Inflate-T | 9 B-/9 A–US/84 AX- | 30 A–US/30 D- | 4 T–US | T |
Inflate-GD | 9 B-/9 A–US/84 BX- | 30 A–US/30 D- | 4 T–US | XT |
NoInfl-XT | 9 B-/9 A–US/84 AX- | 30 C–US/30 D- | 4 T–US | XT |
NoInfl-T | 9 B-/9 A–US/84 AX- | 30 C–US/30 D- | 4 T–US | T |
NoInfl-GD | 9 B-/9 A–US/84 BX- | 30 C–US/30 D- | 4 T–US | XT |
Note. The numbers preceding the letters in Phases 1–3 indicate the total number of presentations of the stimuli (A, B, C, D, T, and X). Slashes represent interspersed trials. The US was footshock. ‘-’ represents nonreinforced presentations of a CS. ‘XT’ and ‘T’ indicate the type of stimulus that was presented at test, compound or element, respectively.